Cardiovascular & kidney outcomes: LEADER
Lowering blood sugar is not the same as preventing the events diabetes causes.
When a diabetes drug started preventing cardiovascular events
Lowering blood sugar is not the same as preventing the events diabetes causes. The LEADER trial asked the harder question directly: in 9,340 adults with type 2 diabetes at high cardiovascular risk, did liraglutide reduce actual heart attacks, strokes, and cardiovascular deaths?
It did, in that population. The primary composite was the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke, and it occurred in 13.0% on liraglutide against 14.9% on placebo, hazard ratio 0.87; a pre-specified analysis found a kidney benefit too. This unit reads those outcomes carefully, including what was significant, what was not, and why nothing here reaches the weight-management product or people without diabetes.